Page last updated: 2024-09-05

paromomycin and Black Fever

paromomycin has been researched along with Black Fever in 96 studies

Research

Studies (96)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	17 (17.71)	18.2507
2000's	20 (20.83)	29.6817
2010's	48 (50.00)	24.3611
2020's	11 (11.46)	2.80

Authors

Authors	Studies
Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X	1
Blaser, A; Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Yardley, V	1
Atnafu, S; Hailu, A; Medhin, G; Mohammed, R; Tamiru, A	1
Abdella, AM; Dessie, G; Endale, HT; Malik, T; Mengstie, TA; Mohammed, R; Mulaw, T	1
Coelho, AC; Coser, EM; Cotrim, PC; da L Oliveira, V; Ferreira, BA; Martins, TFC; Pinto, MM; Rocha, MC; Yamashiro-Kanashiro, EH	1
Alcoba, G; Alvar, J; Alves, F; Dorlo, TPC; Egondi, T; Fikre, H; Ismail Omer Haroun, A; Khalil, EAG; Mbui, J; Mekonnen, T; Mersha, D; Mohammed, R; Musa Younis, B; Musa, AM; Muthoni Ouattara, G; Nakanwagi, P; Njenga, S; Nour, A; Olobo, J; Omollo, T; Ritmeijer, K; Sagaki, P; Sisay, K; Solomos, A; Taha Ahmed Elmukashfi, E; Verrest, L; Wasunna, M	1
Alves, F; Beijnen, JH; Dorlo, TPC; Musa, AM; Roseboom, IC; Rosing, H; Thijssen, B; Younis, BM	1
Henriquez-Figuereo, A; Moreno, E; Plano, D; Sanmartin, C	1
Alves, F; Chu, WY; Dorlo, TPC; Huitema, ADR; Mbui, J; Mohammed, R; Musa, AM; Njenga, S; Olobo, J; Ritmeijer, K; Roseboom, IC; Solomos, A; Verrest, L; Wasunna, M	1
Apostolidis, K; Buono, A; Chatzis, MK; Kasabalis, D; Leontides, LS; Petanides, T; Polizopoulou, ZS; Saridomichelakis, MN; Steiner, JM; Suchodolski, JS; Xenoulis, PG	1
Alvar, J; Alves, F; Bern, C; Burza, S; Das, P; Das, VNR; Goyal, V; Hightower, A; Lima, N; Pandey, K; Rijal, S; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T	1
Berriman, M; Blackburn, G; Carter, KC; Coombs, GH; Cotton, JA; Downing, T; Dujardin, JC; Imamura, H; Rijal, S; Sanders, M; Shaw, CD; Westrop, GD	1
Beijnen, JH; Dorlo, TPC; Mbui, J; Roseboom, IC; Rosing, H; Thijssen, B	1
Apostolidis, K; Athanasiou, LV; Chatzis, MK; Ikonomopoulos, J; Kasabalis, D; Leontides, LS; Mataragka, A; Petanides, T; Saridomichelakis, MN; Xenoulis, PG	1
Gedda, MR; Mudavath, SL; Parvez, S; Singh, A; Singh, OP; Sundar, S; Verma, A; Yadagiri, G	1
Alves, F; Aman, R; Beijnen, JH; Chakravarty, J; Dorlo, TPC; Hailu, A; Hailu, W; Huitema, ADR; Hurissa, Z; Khalil, EAG; Kokwaro, G; Kshirsagar, SA; Makonnen, E; Mekonnen, Y; Mudawi, M; Musa, AM; Rai, M; Sundar, S; Tesfaye, S; Verrest, L; Wasunna, M; Younis, BM	1
Asensi-Diez, R; Furones Araujo, D; Gallego Fernández, C	1
Caljon, G; Cos, P; Delputte, P; Hendrickx, S; Mabille, D; Maes, L; Van den Kerkhof, M	1
Alvar, J; Alves, F; Balasegaram, M; Boer, MD; Ellis, S; Faiz, A; Goyal, V; Haque, R; Jamil, K; Rahman, R; Rijal, S; Samad, R; Sharma, B; Strub-Wourgaft, N	1
Arrese Estrada, J; Cnops, L; Darcis, G; de Leval, L; Giot, JB; Hayette, MP; Leonard, P; Moutschen, M; Tassin, F; Van der Auwera, G	1
Bhandari, V; Deep, DK; Dujardin, JC; Salotra, P; Singh, R; Sundar, S; Verma, A	1
Fernando, SD; Rajapakse, S; Rodrigo, C; Weeratunga, P	1
Singh, A; Sundar, S	1
Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V	1
Alvar, J; Alves, F; Balasegaram, M; Bern, C; Burza, S; Das, P; Ellis, S; Goyal, V; Hightower, A; Lima, N; Mahajan, R; Pandey, K; Rabi Das, VN; Rijal, S; Sharma, B; Singh, RS; Singh, SN; Strub-Wourgaft, N; Sunyoto, T; Topno, RK	1
Alvar, J; Boelaert, M; Das, P; Mondal, D; Rijal, S; Sundar, S	1
Afzal, I; Akhtar, S; Jahan, S; Sarwar, HS; Satoskar, AR; Shahnaz, G; Sohail, MF; Varikuti, S; Yasinzai, M	1
Agarwal, N; Arya, SC	1
Das, P; Das, S; Pandey, K; Rabidas, V; Rani, M; Sahoo, GC	1
Ben Messaoud, N; Ben Salah, A; Buffet, PA; Grogl, M; Kidar, A; Kopydlowski, KM; Kreishman-Deitrick, M; Morizot, G; Nielsen, CJ; Novitt-Moreno, A; Ransom, JH; Smith, PL; Zaâtour, A	1
Assefa, A; Belew, Z; Boelaert, M; Diro, E; Gebregziabiher, B; Hailu, A; Lakew, W; Lynen, L; van Griensven, J	1
Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Maes, L; Mondelaers, A	1
Alcoba, G; Alnour, M; Atia, AM; Boulle, P; Chappuis, F; Elhag, MS; Mumina, A; Shah, S; Tayler-Smith, K; van Griensven, J; Zachariah, R	1
Cos, P; Delputte, P; Dujardin, JC; Hendrickx, S; Khanal, B; Leemans, A; Maes, L; Mondelaers, A; Rijal, S	1
Bhuiyan, AT; Bhuiyan, MA; Desjeux, P; Dhalaria, P; Faiz, MA; Ghosh, RS; Haque, R; Hassan, SM; Jamil, KM; Kelly, H; Khan, MM; Kochhar, S; Kumar, A; Rahman, R	1
Beyers, J; Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A	1
Alvar, J; Balasegaram, M; Hailu, A; Juma, R; Khalil, EA; Musa, A; Olobo, J; Wasunna, M; Wells, S	1
Ali, V; Bimal, S; Das, P; Das, VNR; Lal, CS; Murti, K; Pal, B; Pandey, K; Siddiqi, NA; Topno, RK; Verma, N; Verma, RB	1
Alirol, E; Alvar, J; Alves, F; Balasegaram, M; Chappuis, F; Diro, E; Ellis, S; Hailu, A; Jameneh, A; Khalil, EA; Kimutai, R; Makonnen, E; Mohammed, R; Musa, AM; Musa, B; Njoroge, S; Okello, L; Olobo, J; Omollo, R; Rashid, J; Ritmeijer, K; Sagaki, P; Salman, K; Soipei, P; Strub, N; Wasunna, M	1
Thakur, CP	1
Davidson, RN; den Boer, M; Ritmeijer, K	1
Olliaro, P; Sundar, S	1
Darley, S; Laxminarayan, R; Olliaro, P; Sundar, S	1
Agarwal, D; Agrawal, N; Arora, R; Chakravarty, J; Rai, M; Sundar, S	1
Khan, W; Kumar, N	1
Barragán, P; López-Velez, R; Olmo, M; Podzamczer, D	1
Balasegaram, M; Boelaert, M; Faiz, MA; Meheus, F; Olliaro, P; Rijal, S; Sundar, S	1
Gupta, S; Sane, SA; Shakya, N	1
Murray, HW	2
Olliaro, PL	1
Ahmed, O; Alobo, M; Balasegaram, M; Edwards, T; El-Hassan, A; Ellis, S; Fadlalla, A; Hailu, A; Hailu, W; Hurissa, Z; Kesusu, J; Khalil, E; Kinuthia, J; Kirigi, G; Kirui, F; Koummuki, Y; Lodenyo, H; Makonnen, E; Manduku, V; Mbui, J; Mengistu, G; Mucee, G; Mueller, M; Musa, A; Musibi, A; Mutea, D; Muthami, L; Mutuma, G; Njoroge, S; Omollo, R; Owiti, R; Raheem, M; Rashid, J; Royce, C; Smith, P; Tesfaye, S; Wasunna, M; Weldegebreal, T; Yifru, S	1
Balasegaram, M; Edwards, T; El-Hassan, A; Fadlalla, A; Hailu, A; Khalil, E; Kokwaro, G; Mudawi, M; Musa, AM; Omollo, R; Royce, C; Wasunna, M; Younis, B	1
Ali, N; Banerjee, A; De, M	1
Alam, S; Arora, R; Balasegaram, M; Chakravarty, J; Das, P; Ellis, S; Kumari, P; Lal, CS; Modabber, F; Nawin, K; Olliaro, P; Pandey, K; Rai, M; Sharma, B; Sinha, PK; Strub-Wourgaft, N; Sundar, S; Vaillant, M; Verma, DK; Verma, N	1
Boelaert, M; van Griensven, J	1
Alvar, J; Arana, B; Battacharya, S; Das, P; Kroeger, A; Matlashewski, G; Mondal, D; Rijal, S; Sinha, PK; Sundar, S; Zilberstein, D	1
Croft, SL; Olliaro, P	1
Bimal, S; Das, P; Das, S; Das, VN; Lal, CS; Pandey, K; Siddiqui, NA; Singh, D; Sinha, PK; Topno, RK; Verma, N; Verma, RB	1
Arora, SK; Khan, W; Kumar, N; Kumar, R; Singh, S	1
Bhandari, V; Deep, DK; Dujardin, JC; Kulshrestha, A; Prajapati, VK; Ramesh, V; Salotra, P; Schonian, G; Stark, O; Sundar, S	1
Bhandari, V; Carter, K; Cos, P; Dujardin, JC; Hendrickx, S; Inocêncio da Luz, RA; Kuypers, K; Lonchamp, J; Maes, L; Rijal, S; Salotra, P; Shaw, CD; Sundar, S	1
Abuzaid, AA; Ahmed, O; Apadet, L; Balasegaram, M; Edwards, T; El-Hassan, A; Ellis, S; Fadlalla, A; Hailu, A; Hailu, W; Hurissa, Z; Kesusu, J; Khalil, E; Kimutai, R; Kirigi, G; Lodenyo, H; Makonnen, E; Manduku, V; Mbui, J; Mekonnen, Y; Mengistu, G; Mucee, G; Mueller, M; Musa, A; Musa, B; Mutea, D; Mutuma, G; Ndegwa, S; Njoroge, S; Olobo, J; Omollo, R; Owiti, R; Rashid, J; Sagaki, P; Tafes, H; Wasunna, M; Weldegebreal, T; Yifru, S	1
Athanasiou, LV; Kontos, VI; Rallis, TS; Saridomichelakis, MN; Spanakos, G	1
Chakravarty, J; Sundar, S	1
Boelaert, M; Bryceson, AD; Croft, SL; Desjeux, P; Guerin, PJ; Olliaro, P; Sundar, S; Wasunna, MK	1
Carter, KC; Mullen, AB; Pereira, OC; Spickett, C; Sundar, S	1
Desjeux, P	1
Kumar, A; Sundar, S	1
Pandey, HP; Singh, RK; Sundar, S	1
Croft, SL; Seifert, K; Yardley, V	1
Hu, LT; Klempner, MS; Unnasch, TR	1
Bhattacharya, SK; Jha, TK; Sinha, PK; Sundar, S; Thakur, CP	1
Collin, SM; Davidson, RN; Gatluak, F; Keus, K; Melaku, Y; Ritmeijer, K	1
Hale, V	1
Calza, L; Manfredi, R; Marinacci, G; Passarini, B	1
Baat, DB; Hassan, K; Hassan, M	1
Boer, C; Davidson, R; de Jong, J; de Wilde, E; Seaman, J; Sondorp, E; Wilkinson, R	1
Allen, S; Croft, SL; McCoy, N; Neal, RA; Olliaro, P	1
Bryceson, AD; Davidson, RN; Moody, A; Pryce, D; Seaman, J; Sondorp, HE	1
Buffet, PA; Derouin, F; Garin, YJ; Nassar, N; Sulahian, A	1
Bandinelli, P; Guidi, G; Mancianti, F; Poli, A; Sozzi, S	1
Derouin, F; Gangneux, JP; Garin, YJ; Sulahian, A	1
del Giudice, P; Dellamonica, P; Haas, H; Lacour, JP; Le Fichoux, Y; Marty, P; Perrin, C; Pratlong, F	1
Cavalcante, R; Fonseca de Castro, JA; Furtado Campos, JH; Miles, MA; Olliaro, PL; Tavares, JP; Vexenat, JA	1
Akhoury, S; Jha, S; Jha, TK; Kanyok, TP; Olliaro, P; Singh, IJ; Singh, NK; Singhania, BL; Thakur, CP	1
Ciaramella, P; Cortese, L; de Luna, R; Gradoni, L; Oliva, G; Orsini, S; Persechino, A; Scalone, A	1
Craciunescu, DG; Loiseau, PM; Mbongo, N; Robert-Gero, M	1
Jha, TK; Olliaro, P	1
Baillie, AJ; Carter, KC; Mullen, AB; Williams, D	1
Belloli, C; Bertini, S; Carli, S; Crescenzo, G; Mengozzi, G; Ormas, P; Zaghini, A	1
Murray , HW	1
Sundar, S	2
Zijlstra, EE	1

Reviews

14 review(s) available for paromomycin and Black Fever

Article	Year
Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018, Volume: 24, Issue:6 Topics: Amphotericin B; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Drug Compounding; Evidence-Based Medicine; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Survival Analysis; Treatment Outcome	2018
Chemotherapeutics of visceral leishmaniasis: present and future developments. Parasitology, 2018, Volume: 145, Issue:4 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Clinical Trials as Topic; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Meglumine Antimoniate; Paromomycin; Phosphorylcholine; Psychodidae; Sheep; South America; Treatment Outcome	2018
Paromomycin. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, Volume: 103, Issue:7 Topics: Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Communicable Diseases, Emerging; Drug Resistance; Humans; Leishmaniasis, Visceral; Paromomycin	2009
Drug combinations for visceral leishmaniasis. Current opinion in infectious diseases, 2010, Volume: 23, Issue:6 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Cost-Benefit Analysis; Drug Resistance; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine	2010
Visceral leishmaniasis: elimination with existing interventions. The Lancet. Infectious diseases, 2011, Volume: 11, Issue:4 Topics: Amphotericin B; Antiprotozoal Agents; Communicable Disease Control; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine	2011
Leishmaniasis chemotherapy--challenges and opportunities. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, Volume: 17, Issue:10 Topics: Anti-HIV Agents; Antiprotozoal Agents; Clinical Trials as Topic; Coinfection; Drug Discovery; HIV; HIV Infections; Humans; India; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Paromomycin; Research	2011
Leishmaniasis: an update of current pharmacotherapy. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:1 Topics: Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Drug Therapy, Combination; Humans; Leishmania donovani; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Species Specificity; Treatment Outcome	2013
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. The Lancet. Infectious diseases, 2002, Volume: 2, Issue:8 Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Asia, Western; Brazil; Developing Countries; Dogs; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Sudan	2002
Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert review of anti-infective therapy, 2004, Volume: 2, Issue:2 Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Clinical Trials as Topic; Deoxycholic Acid; Drug Combinations; Drug Costs; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphatidylcholines; Phosphatidylglycerols; Phosphorylcholine; Practice Guidelines as Topic	2004
Visceral leishmaniasis (kala-azar): challenges ahead. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Humans; India; Leishmania; Leishmaniasis, Visceral; Lipids; Paromomycin; Public Health; Sensitivity and Specificity	2006
Current scenario of drug development for leishmaniasis. The Indian journal of medical research, 2006, Volume: 123, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Design; Humans; Leishmania; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Models, Chemical; Paromomycin; Phosphorylcholine	2006
Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Archives of dermatology, 1998, Volume: 134, Issue:2 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Antigens, Protozoan; Antiprotozoal Agents; Blotting, Western; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Injections, Intradermal; Leishmania infantum; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Meglumine; Middle Aged; Paromomycin	1998
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2000, Volume: 4, Issue:3 Topics: Adult; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Child; Humans; Leishmania donovani; Leishmaniasis, Visceral; Mice; Paromomycin; Phosphorylcholine; Treatment Outcome	2000
Treatment of visceral leishmaniasis. Medical microbiology and immunology, 2001, Volume: 190, Issue:1-2 Topics: Administration, Oral; Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Paromomycin; Pentamidine	2001

Trials

22 trial(s) available for paromomycin and Black Fever

Article	Year
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Adult; Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome	2023
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis. The Journal of antimicrobial chemotherapy, 2023, 11-06, Volume: 78, Issue:11 Topics: Adult; Antiprotozoal Agents; Child; Humans; Kenya; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome; Uganda	2023
Evaluation of nephrotoxicity and ototoxicity of aminosidine (paromomycin)-allopurinol combination in dogs with leishmaniosis due to Leishmania infantum: A randomized, blinded, controlled study. Experimental parasitology, 2019, Volume: 206 Topics: Allopurinol; Animals; Cochlea; Creatinine; Dog Diseases; Dogs; Double-Blind Method; Drug Combinations; Evoked Potentials, Auditory, Brain Stem; Female; Hearing; Hearing Loss; Injections, Subcutaneous; Kidney; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Neurologic Examination; Paromomycin; Random Allocation; Vestibule, Labyrinth	2019
A randomized, blinded, controlled clinical trial comparing the efficacy of aminosidine (paromomycin)-allopurinol combination with the efficacy of meglumine antimoniate-allopurinol combination for the treatment of canine leishmaniosis due to Leishmania inf Experimental parasitology, 2020, Volume: 214 Topics: Allopurinol; Animals; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Injections, Subcutaneous; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine Antimoniate; Paromomycin; Trypanocidal Agents	2020
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:5 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Bangladesh; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Phosphorylcholine; Recurrence; Treatment Outcome; Young Adult	2017
Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; India; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Phosphorylcholine; Prospective Studies; Treatment Outcome; Young Adult	2018
TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasis. British journal of pharmacology, 2014, Volume: 171, Issue:5 Topics: Adult; Antiprotozoal Agents; Cells, Cultured; Dendritic Cells; Drug Combinations; Female; HEK293 Cells; Humans; Interleukin-10; Interleukin-12; Leishmaniasis, Visceral; Male; Myeloid Differentiation Factor 88; Paromomycin; Phosphorylcholine; Toll-Like Receptor 9	2014
Parasite load decrease during application of a safe and easily applied antileishmanial aminoglycoside cream. PLoS neglected tropical diseases, 2014, Volume: 8, Issue:5 Topics: Administration, Topical; Adolescent; Adult; Aged; Dermis; Drug Combinations; Female; Gentamicins; Humans; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Parasite Load; Paromomycin; Trypanocidal Agents; Young Adult	2014
Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh. PLoS neglected tropical diseases, 2015, Volume: 9, Issue:10 Topics: Adolescent; Adult; Anti-Infective Agents; Bangladesh; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Female; Health Care Costs; Humans; Injections, Intramuscular; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Treatment Outcome; Young Adult	2015
Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study. The British journal of dermatology, 2017, Volume: 177, Issue:2 Topics: Administration, Oral; Adult; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Pilot Projects; Treatment Outcome	2017
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2009, Sep-15, Volume: 49, Issue:6 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; India; Injections, Intramuscular; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Time Factors; Treatment Outcome; Young Adult	2009
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS neglected tropical diseases, 2010, Oct-26, Volume: 4, Issue:10 Topics: Adolescent; Adult; Africa, Eastern; Antiprotozoal Agents; Child; Child, Preschool; Female; Geography; Humans; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Treatment Outcome; Young Adult	2010
Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS neglected tropical diseases, 2010, Oct-26, Volume: 4, Issue:10 Topics: Adolescent; Adult; Antiprotozoal Agents; Bone Marrow; Child; Child, Preschool; Female; Humans; Injections, Intramuscular; Leishmania donovani; Leishmaniasis, Visceral; Male; Microscopy; Middle Aged; Paromomycin; Sudan; Time Factors; Treatment Outcome; Young Adult	2010
Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet (London, England), 2011, Feb-05, Volume: 377, Issue:9764 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Creatinine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemoglobins; Humans; India; Leishmaniasis, Visceral; Liver; Liver Function Tests; Male; Middle Aged; Paromomycin; Phosphorylcholine; Recurrence; Young Adult	2011
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS neglected tropical diseases, 2012, Volume: 6, Issue:6 Topics: Adolescent; Adult; Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Treatment Outcome; Young Adult	2012
Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial. Veterinary parasitology, 2013, Feb-18, Volume: 192, Issue:1-3 Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Bone Marrow; DNA, Protozoan; Dog Diseases; Dogs; Drug Dosage Calculations; Female; Fluorescent Antibody Technique, Indirect; Injections, Subcutaneous; Leishmania infantum; Leishmaniasis, Visceral; Lymph Nodes; Male; Paromomycin; Pilot Projects; Polymerase Chain Reaction; Treatment Outcome	2013
Injectable paromomycin for Visceral leishmaniasis in India. The New England journal of medicine, 2007, Jun-21, Volume: 356, Issue:25 Topics: Adolescent; Adult; Amphotericin B; Animals; Antiprotozoal Agents; Audiometry; Child; Child, Preschool; Disease Reservoirs; Female; Hearing Disorders; Humans; India; Infusions, Intravenous; Injections, Intramuscular; Kidney Diseases; Leishmania donovani; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Prospective Studies; Treatment Outcome	2007
Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995, Volume: 21, Issue:1 Topics: Adolescent; Adult; Aged; Amebicides; Amphotericin B; Animals; Anti-Bacterial Agents; Antimony; Child; Child, Preschool; Drug Administration Schedule; Drug Carriers; Female; Humans; Infant; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Liposomes; Lymph Nodes; Male; Middle Aged; Paromomycin; Recurrence; Spleen; Sudan	1995
Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. The Journal of infectious diseases, 1993, Volume: 168, Issue:3 Topics: Adolescent; Adult; Antimony Sodium Gluconate; Child; Child, Preschool; Disease Outbreaks; Drug Therapy, Combination; Female; Giardiasis; Humans; Infant; Leishmaniasis, Visceral; Malaria; Male; Middle Aged; Nutrition Disorders; Paromomycin; Pregnancy; Sudan; Weight Loss	1993
Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis. Veterinary parasitology, 1997, Volume: 71, Issue:4 Topics: Amebicides; Animals; Antibodies, Protozoan; Antigen-Antibody Complex; Antigens, Protozoan; Antimony Sodium Gluconate; Antiprotozoal Agents; Dog Diseases; Dogs; Female; Immunoglobulin G; Leishmania infantum; Leishmaniasis, Visceral; Male; Paromomycin; Proteinuria; Time Factors	1997
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (Clinical research ed.), 1998, Apr-18, Volume: 316, Issue:7139 Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimony Sodium Gluconate; Child; Dose-Response Relationship, Drug; Humans; Injections, Intramuscular; Leishmaniasis, Visceral; Middle Aged; Paromomycin; Risk Assessment; Schistosomicides; Treatment Outcome	1998
The treatment of kala-azar: old and new options. Tropical and geographical medicine, 1992, Volume: 44, Issue:3 Topics: Amphotericin B; Antimony; Humans; Ketoconazole; Leishmaniasis, Visceral; Paromomycin	1992

Other Studies

60 other study(ies) available for paromomycin and Black Fever

Article	Year
Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Amidines; Animals; Antiprotozoal Agents; Biological Availability; Cricetinae; Disease Models, Animal; Drug Discovery; Female; Furans; Humans; In Vitro Techniques; Leishmania donovani; Leishmania major; Leishmania mexicana; Leishmaniasis, Visceral; Liver; Mesocricetus; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutagenicity Tests; Parasitemia; Parasitic Sensitivity Tests; Spleen; Tissue Distribution	2010
Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of medicinal chemistry, 2018, 03-22, Volume: 61, Issue:6 Topics: Animals; Antiparasitic Agents; Cell Membrane Permeability; Chagas Disease; Cricetinae; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ERG1 Potassium Channel; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Mesocricetus; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2018
Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia. PLoS neglected tropical diseases, 2021, Volume: 15, Issue:8 Topics: Adolescent; Adult; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Drug Dosage Calculations; Drug Therapy, Combination; Ethiopia; Female; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Retrospective Studies; Treatment Outcome; Young Adult	2021
Assessment of serum amylase, lipase and associated factors among patients with visceral leishmaniasis treated with sodium stibogluconate/paromomycin at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. PloS one, 2021, Volume: 16, Issue:10 Topics: Adolescent; Adult; Amylases; Antimony Sodium Gluconate; Antiprotozoal Agents; Cross-Sectional Studies; Ethiopia; Female; Hospitals, Special; Humans; Leishmaniasis, Visceral; Lipase; Male; Paromomycin; Treatment Outcome; Young Adult	2021
Isolation, typing, and drug susceptibility of Leishmania (Leishmania) infantum isolates from dogs of the municipality of Embu das Artes, an endemic region for canine leishmaniasis in Brazil. Parasitology research, 2022, Volume: 121, Issue:9 Topics: Animals; Brazil; Dog Diseases; Dogs; Humans; Leishmania infantum; Leishmaniasis, Visceral; Paromomycin	2022
Development and validation of an ultra-high performance liquid chromatography coupled to tandem mass spectrometry method for the quantification of the antileishmanial drug paromomycin in human skin tissue. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2022, Nov-15, Volume: 1211 Topics: Antiprotozoal Agents; Chromatography, High Pressure Liquid; Humans; Leishmaniasis, Visceral; Paromomycin; Reproducibility of Results; Tandem Mass Spectrometry	2022
Exploring Novel Drug Combinations: The Therapeutic Potential of Selanyl Derivatives for Leishmania Treatment. Molecules (Basel, Switzerland), 2023, Aug-03, Volume: 28, Issue:15 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Combinations; Humans; Leishmania infantum; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Paromomycin	2023
Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India. PLoS neglected tropical diseases, 2019, Volume: 13, Issue:9 Topics: Adolescent; Amphotericin B; Antiprotozoal Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; India; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Recurrence; Treatment Outcome	2019
Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains. Antimicrobial agents and chemotherapy, 2019, 12-20, Volume: 64, Issue:1 Topics: Animals; Antiprotozoal Agents; Drug Resistance; Female; Genomics; Humans; Leishmania donovani; Leishmaniasis, Visceral; Lipidomics; Macrophages; Metabolomics; Mice; Mice, Inbred BALB C; Nepal; Parasitic Sensitivity Tests; Paromomycin; Polymorphism, Genetic	2019
Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. Journal of pharmaceutical and biomedical analysis, 2020, Jun-05, Volume: 185 Topics: Adsorption; Africa, Eastern; Antiprotozoal Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Humans; Injections, Intramuscular; Leishmaniasis, Visceral; Limit of Detection; Paromomycin; Reference Standards; Reproducibility of Results; Tandem Mass Spectrometry; Trichloroacetic Acid	2020
Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Scientific reports, 2020, 07-22, Volume: 10, Issue:1 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Cell Line; Emulsions; Leishmania donovani; Leishmaniasis, Visceral; Lipids; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paromomycin; Particle Size; Phosphorylcholine	2020
Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients. Clinical pharmacokinetics, 2021, Volume: 60, Issue:11 Topics: Antimony Sodium Gluconate; Antiprotozoal Agents; Humans; Kenya; Leishmaniasis, Visceral; Paromomycin	2021
[Hearing loss associated with paromomycin treatment in a patient with visceral leishmaniasis]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2017, May-01, Volume: 41, Issue:3 Topics: Adult; Antiparasitic Agents; Hearing Loss; Humans; Leishmaniasis, Visceral; Male; Paromomycin	2017
Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum. PLoS neglected tropical diseases, 2017, Volume: 11, Issue:5 Topics: Animals; Antiprotozoal Agents; Cricetinae; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Mice; Paromomycin; Phosphorylcholine	2017
Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy. BMC infectious diseases, 2017, 07-07, Volume: 17, Issue:1 Topics: Amphotericin B; Antiprotozoal Agents; Biopsy; Female; Humans; Immunocompromised Host; Leishmania; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Middle Aged; Paromomycin; Phosphorylcholine; Polymerase Chain Reaction; Recurrence	2017
Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani. International journal for parasitology. Drugs and drug resistance, 2017, Volume: 7, Issue:3 Topics: Amlodipine; Animals; Anti-Bacterial Agents; Antimony; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Drug Resistance; Gene Expression Profiling; Humans; Leishmania donovani; Leishmaniasis, Visceral; Life Cycle Stages; Macrophages; Metabolic Networks and Pathways; Mice; Nitric Oxide; Parasitic Sensitivity Tests; Paromomycin; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Verapamil	2017
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Infectious diseases of poverty, 2018, Aug-13, Volume: 7, Issue:1 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Female; Humans; Leishmania donovani; Leishmania tropica; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Male; Middle Aged; Myocardial Infarction; Paromomycin; Patient Safety; Pharmacovigilance; Phosphorylcholine; Quality of Life; Recurrence; Survival Analysis	2018
Eliminating visceral leishmaniasis in South Asia: the road ahead. BMJ (Clinical research ed.), 2019, Jan-22, Volume: 364 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Bangladesh; Disease Vectors; Drug Therapy, Combination; Epidemiological Monitoring; Humans; India; International Cooperation; Leishmaniasis, Visceral; Neglected Diseases; Nepal; Paromomycin; Phosphorylcholine; Program Development; Program Evaluation	2019
Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis. Nanomedicine (London, England), 2019, Volume: 14, Issue:4 Topics: Animals; Antiprotozoal Agents; Cells, Cultured; Flow Cytometry; Lectins, C-Type; Leishmania donovani; Leishmaniasis, Visceral; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Nanoparticles; Paromomycin; Receptors, Cell Surface	2019
Comment on: leishmaniasis: an update of current pharmacotherapy. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:9 Topics: Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Organometallic Compounds; Paromomycin; Phosphorylcholine	2013
Clinical aspects of paediatric visceral leishmaniasis in North-west Ethiopia. Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:1 Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Comorbidity; Cross-Sectional Studies; Ethiopia; Female; HIV Infections; Humans; Intestinal Diseases, Parasitic; Leishmaniasis, Visceral; Male; Malnutrition; Paromomycin; Prospective Studies; Treatment Outcome; Vitamin D Deficiency	2015
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:8 Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2015
Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan. Tropical medicine & international health : TM & IH, 2015, Volume: 20, Issue:12 Topics: Adolescent; Adult; Anemia; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Infant; Leishmaniasis, Visceral; Lost to Follow-Up; Male; Malnutrition; Paromomycin; Patient Selection; Prevalence; Recurrence; Retrospective Studies; Sudan; Treatment Failure	2015
Comparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant Strain. PloS one, 2015, Volume: 10, Issue:10 Topics: Animals; Antiprotozoal Agents; Drug Resistance; Female; Genetic Fitness; In Vitro Techniques; Leishmania donovani; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Paromomycin	2015
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:7 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Selection, Genetic; Virulence	2016
The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, Volume: 110, Issue:6 Topics: Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Biomedical Research; Capacity Building; Cooperative Behavior; Endemic Diseases; Humans; Leishmaniasis, Visceral; Neglected Diseases; Paromomycin	2016
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. Clinical drug investigation, 2017, Volume: 37, Issue:3 Topics: Administration, Intravenous; Adolescent; Adult; Africa, Eastern; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Coinfection; Drug Therapy, Combination; Female; HIV Infections; Humans; Leishmaniasis, Visceral; Male; Middle Aged; Paromomycin; Pharmacovigilance; Prospective Studies; Recurrence; Treatment Outcome; Young Adult	2017
Tetany in kala azar patients treated with paromomycin. The Indian journal of medical research, 2008, Volume: 127, Issue:5 Topics: Adolescent; Anti-Bacterial Agents; Calcium; Child; Child, Preschool; Female; Humans; Leishmaniasis, Visceral; Male; Paromomycin; Randomized Controlled Trials as Topic; Tetany	2008
Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:1 Topics: Adolescent; Adult; Age Distribution; Aged; Amphotericin B; Anthropometry; Antiprotozoal Agents; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Costs; Female; Humans; India; Infant; Leishmaniasis, Visceral; Liposomes; Male; Middle Aged; Paromomycin; Phosphorylcholine; Sex Distribution	2009
Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India. Tropical medicine & international health : TM & IH, 2009, Volume: 14, Issue:8 Topics: Adolescent; Adult; Amphotericin B; Antiprotozoal Agents; Child; Cost-Benefit Analysis; Direct Service Costs; Drug Administration Schedule; Drug Costs; Female; Hospital Costs; Humans; India; Leishmaniasis, Visceral; Male; Paromomycin; Phosphorylcholine; Practice Guidelines as Topic; Young Adult	2009
Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation. Journal of drug targeting, 2011, Volume: 19, Issue:4 Topics: Albumins; Animals; Antiprotozoal Agents; Cell Line; Drug Carriers; Drug Delivery Systems; Leishmania donovani; Leishmaniasis, Visceral; Mice; Microspheres; Paromomycin	2011
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. The American journal of tropical medicine and hygiene, 2010, Volume: 83, Issue:1 Topics: AIDS-Related Opportunistic Infections; HIV; HIV Infections; HIV-1; Humans; Itraconazole; Leishmaniasis; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Opportunistic Infections; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Recurrence; Treatment Failure	2010
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS neglected tropical diseases, 2010, Sep-07, Volume: 4, Issue:9 Topics: Amphotericin B; Antiprotozoal Agents; Bangladesh; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; India; Leishmaniasis, Visceral; Models, Statistical; Nepal; Paromomycin; Phosphorylcholine	2010
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. Experimental parasitology, 2011, Volume: 127, Issue:2 Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycosides; Leishmania donovani; Leishmaniasis, Visceral; Lymphocytes; Male; Mesocricetus; Paromomycin; Phagocytosis; Phosphorylcholine; Random Allocation; Reactive Nitrogen Species; Reactive Oxygen Species; Vanillic Acid	2011
Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Future microbiology, 2010, Volume: 5, Issue:9 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Humans; India; Leishmania donovani; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Treatment Outcome	2010
Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:4 Topics: Amines; Animals; Anti-Bacterial Agents; Cells, Cultured; Cricetinae; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunity, Humoral; Immunologic Factors; Interleukin-10; Leishmaniasis, Visceral; Liposomes; Mice; Mice, Inbred BALB C; Paromomycin; Phosphatidylcholines; Transforming Growth Factor beta	2011
Combination therapy for visceral leishmaniasis. Lancet (London, England), 2011, Feb-05, Volume: 377, Issue:9764 Topics: Amphotericin B; Antiprotozoal Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; India; Leishmaniasis, Visceral; Paromomycin; Phosphorylcholine; Randomized Controlled Trials as Topic	2011
Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India. Journal of clinical microbiology, 2012, Volume: 50, Issue:4 Topics: Adult; Antiprotozoal Agents; Female; Humans; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Paromomycin; Secondary Prevention	2012
Paromomycin-loaded albumin microspheres: efficacy and stability studies. Drug testing and analysis, 2013, Volume: 5, Issue:6 Topics: Albumins; Amebicides; Animals; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Drug Stability; Humans; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Microspheres; Paromomycin	2013
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS neglected tropical diseases, 2012, Volume: 6, Issue:5 Topics: Adolescent; Adult; Animals; Antiprotozoal Agents; Child; Female; Humans; India; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Male; Middle Aged; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine; Young Adult	2012
Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS neglected tropical diseases, 2012, Volume: 6, Issue:5 Topics: Animals; Antimony; Antiprotozoal Agents; Cricetinae; Drug Resistance; Genomic Instability; Humans; India; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Visceral; Mesocricetus; Mice; Mice, Inbred BALB C; Nepal; Parasitic Sensitivity Tests; Parasitology; Paromomycin; Selection, Genetic; Serial Passage	2012
The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrobial agents and chemotherapy, 2003, Volume: 47, Issue:5 Topics: Amphotericin B; Animals; Antimony Sodium Gluconate; Buthionine Sulfoximine; Drug Resistance; Female; Glutathione; Leishmania donovani; Leishmaniasis, Visceral; Male; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine	2003
[Therapeutic options for visceral leishmaniasis]. Medecine et maladies infectieuses, 2005, Volume: 35 Suppl 2 Topics: Aminoquinolines; Amphotericin B; Antiprotozoal Agents; Humans; Leishmaniasis, Visceral; Paromomycin	2005
Challenges in the management of visceral leishmaniasis. Indian pediatrics, 2005, Volume: 42, Issue:6 Topics: Amebicides; Amphotericin B; Antimony Sodium Gluconate; Antiparasitic Agents; Antiprotozoal Agents; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique, Indirect; Humans; Immunoglobulin G; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine	2005
Taking a bite out of vector-transmitted infectious diseases. The New England journal of medicine, 2007, Jun-21, Volume: 356, Issue:25 Topics: Animals; Antiprotozoal Agents; Communicable Disease Control; Communicable Diseases; Disease Reservoirs; Disease Transmission, Infectious; Disease Vectors; Humans; Leishmaniasis, Visceral; Paromomycin; Psychodidae; Vaccines	2007
Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. The American journal of tropical medicine and hygiene, 2007, Volume: 77, Issue:1 Topics: Adolescent; Antimony Sodium Gluconate; Antiprotozoal Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Leishmaniasis, Visceral; Male; Medical Records; Paromomycin; Retrospective Studies; Sudan; Treatment Outcome	2007
Straight talk from... Victoria Hale. Nature medicine, 2007, Volume: 13, Issue:11 Topics: Academies and Institutes; Drug Industry; Humans; Leishmaniasis, Visceral; Organizations, Nonprofit; Paromomycin	2007
Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine a International journal of antimicrobial agents, 2008, Volume: 31, Issue:6 Topics: Adult; Amphotericin B; Antiprotozoal Agents; Drug Carriers; HIV Infections; Humans; Leishmaniasis, Visceral; Liposomes; Male; Paromomycin; Pentamidine; Treatment Failure	2008
A new breakthrough in treatment of visceral leishmaniasis in children. JPMA. The Journal of the Pakistan Medical Association, 1995, Volume: 45, Issue:6 Topics: Anemia; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Child; Child, Preschool; Female; Fever; Follow-Up Studies; Hepatomegaly; Humans; Infant; Injections, Intramuscular; Leishmania donovani; Leishmaniasis, Visceral; Leukocyte Count; Male; Pakistan; Paromomycin; Platelet Count; Splenomegaly	1995
The sensitivity of Leishmania species to aminosidine. The Journal of antimicrobial chemotherapy, 1995, Volume: 35, Issue:5 Topics: Animals; Antimony Sodium Gluconate; Cells, Cultured; Cricetinae; Drug Combinations; Drug Interactions; Female; Leishmania; Leishmania donovani; Leishmaniasis, Visceral; Macrophages, Peritoneal; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Microbial Sensitivity Tests; Paromomycin	1995
Therapeutic effect of reference antileishmanial agents in murine visceral leishmaniasis due to Leishmania infantum. Annals of tropical medicine and parasitology, 1996, Volume: 90, Issue:3 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Female; Leishmania infantum; Leishmaniasis, Visceral; Liver Diseases, Parasitic; Lung Diseases, Parasitic; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Parasitology; Paromomycin; Splenic Diseases	1996
Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum. The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:2 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Paromomycin; Spleen	1997
Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin). The American journal of tropical medicine and hygiene, 1998, Volume: 58, Issue:4 Topics: Animals; Antiprotozoal Agents; Disease Reservoirs; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Leishmaniasis, Visceral; Paromomycin; Recurrence; Treatment Outcome	1998
Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Annals of tropical medicine and parasitology, 1998, Volume: 92, Issue:2 Topics: Animals; Antiprotozoal Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Leishmania infantum; Leishmaniasis, Visceral; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Treatment Outcome	1998
Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani. Acta tropica, 1998, Jun-30, Volume: 70, Issue:2 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Drug Synergism; Female; Iridium; Leishmania donovani; Leishmaniasis, Visceral; Macrophages; Mice; Mice, Inbred BALB C; Organometallic Compounds; Paromomycin; Pentamidine; Random Allocation	1998
Clarification of comments on trial of aminosidine in visceral leishmaniasis. BMJ (Clinical research ed.), 1998, Oct-31, Volume: 317, Issue:7167 Topics: Anti-Bacterial Agents; Antimony; Drug Costs; Drug Therapy, Combination; Humans; Leishmaniasis, Visceral; Paromomycin	1998
Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. The Journal of pharmacy and pharmacology, 1998, Volume: 50, Issue:12 Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Female; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Paromomycin; Surface-Active Agents; Treatment Outcome	1998
Drug watch. Indian pediatrics, 1998, Volume: 35, Issue:7 Topics: Administration, Inhalation; Amebicides; Antimony Sodium Gluconate; Antiprotozoal Agents; Diabetes Mellitus, Type 1; Humans; Insulin; Leishmaniasis, Visceral; Paromomycin	1998
Disposition of antimony and aminosidine combination after multiple subcutaneous injections in dogs. Veterinary journal (London, England : 1997), 1999, Volume: 157, Issue:3 Topics: Amebicides; Animals; Antimony; Antiprotozoal Agents; Area Under Curve; Chromatography, Liquid; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Fluorometry; Half-Life; Injections, Subcutaneous; Least-Squares Analysis; Leishmania infantum; Leishmaniasis, Visceral; Male; Meglumine; Meglumine Antimoniate; Organometallic Compounds; Paromomycin; Spectrophotometry, Atomic	1999
Drug resistance in Indian visceral leishmaniasis. Tropical medicine & international health : TM & IH, 2001, Volume: 6, Issue:11 Topics: Aminoquinolines; Amphotericin B; Antimony; Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Resistance; Geography; History, 20th Century; History, 21st Century; Humans; India; Leishmaniasis, Visceral; Paromomycin; Pentamidine; Phosphorylcholine; Treatment Outcome	2001